|
|
|
|
|
|
Sponsored by: |
Eisai Limited |
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00165620 |
To establish the optimum injection rate for E7337 (Iomeron 350) in dynamic CT in patients who have hepatic lesions.The primary endpoint for efficacy is the contrast enhancement effect in the early arterial phase, and the primary safety endpoints are warming sensation and vascular pain.
Condition | Intervention | Phase |
Lesion |
Drug: Iomeprole |
Phase II |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety Study |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteira:
Exclusion Criteria
Items that may affect the safety evaluation of E7337
General concerns relating to the safety of the subject.
Japan | |||||
Kumamoto, Japan, :860-0811 | |||||
Japan, Osaka | |||||
Suita, Osaka, Japan, 565-0871 |
Eisai Limited |
Study Director: | Koichi Tazawa | Eisai Co., Ltd - Development Clinical Research Department. Clinical Research Center |
ClinicalStudyResults.org ID number 1481 
  |
Study ID Numbers: | E7337-J081-141 |
First Received: | September 12, 2005 |
Last Updated: | September 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00165620 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
|